RxDoctor Payments Data

Amy Zhang

Rheumatology · Newark, DENPI 1861811952

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (53.0%), consulting fees and education — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Johnson & Johnson at 54.9% of the total. Reporting peaked in 2024 at $3,110 and has fallen 85.4% since, to $455 in 2025.

$7,581in general payments, 2019–2025

Across 199 payments — averaging $38.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$4K
  • Amgen$477
  • AbbVie$440
  • Novartis$400
  • AstraZeneca$360
  • Lilly USA, LLC$282
  • plus $1K from 18 others

What the payments were for

  • Consulting fees$3,49046%
  • Food & beverage$4,02153%
  • Education$701%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few rheumatology providers in Delawareto place this figure against a meaningful peer group, so we don't.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrenciaAbatacept14$92,401
Hydroxychloroquine Sulfate72$4,198
MethotrexateMethotrexate Sodium72$2,576
Colchicine24$1,943
Prednisone87$1,261
Leflunomide27$642
Allopurinol20$307
Folic Acid18$302
Methylprednisolone22$218
Alendronate Sodium22$191

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Orencia$42$92,40114 claims
Scilex Pharmaceuticals Inc.Colchicine$46$1,94324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few rheumatology providers in Delawareon file to place this against a meaningful peer group, so we don't.

Other rheumatology in Newark

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →